Evidence map›Paper›PMID 35366749›Full record

ArticlePharmacological reports : PR2022

Palbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase.

Tomoyasu Fujii, Jun Kamishikiryo, Tetsuo Morita

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tomoyasu FujiiDepartment of Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, 985 Higashimura, Fukuyama, Hiroshima, 729-0292, Japan. t-fujii@fukuyama-u.ac.jp.ORCID http://orcid.org/0000-0002-5332-8275
Jun KamishikiryoDepartment of Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, 985 Higashimura, Fukuyama, Hiroshima, 729-0292, Japan.
Tetsuo MoritaDepartment of Biochemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, 985 Higashimura, Fukuyama, Hiroshima, 729-0292, Japan.
Fukuyama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLipoprotein metabolism is essential for the growth and proliferation of cancer cells, and is involved in the supply of energy and cellular components. Lipoprotein lipase (LPL) is a very important enzyme in lipoprotein metabolism; however, the details underlying the mechanism of LPL secretion are unclear. Palbociclib is an antitumor drug that inhibits cell cycle progression and suppresses the growth of cancer cells. The effects of palbociclib on energy metabolism, particularly on lipid metabolism, have not been fully elucidated.

methodsWe examined the regulation of LPL secretion, which is primarily involved in lipoprotein metabolism. FM3A mouse mammary tumor cells, which are hormone receptor-positive breast cancer cells, were treated with palbociclib, and the activity and protein levels of secreted LPL were measured. Moreover, the changes in intracellular lipid content were measured by fluorescence staining using Nile Red.

resultsFM3A cells were treated with palbociclib, the activity and protein content of secreted LPL were increased. The stimulatory secretion of LPL by palbociclib was suppressed by an intracellular Ca

conclusionsOur data suggest that palbociclib causes intracellular lipid accumulation in breast cancer cells by stimulating Ca

Indexed as

Breast NeoplasmsLipoprotein LipaseAMP-Activated Protein KinasesAnimalsCalcium-Calmodulin-Dependent Protein Kinase KinaseFemaleHumansLipidsLipoproteinsMicePiperazinesPyridinesAMP-Activated Protein KinasesCalcium-Calmodulin-Dependent Protein Kinase KinaseLipidsLipoprotein LipaseLipoproteinspalbociclibPiperazinesPyridinesAMP-activated protein kinaseBreast cancerLipid accumulationLipoprotein lipasePalbociclib

Identifiers

PMID35366749
OpenAlexW4225346159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.